Which of the following statements comparing the serotonin-dopamine antagonists (SDAs) with dopamine receptor antagonists (DRAs) is true?
a.The DRAs remain the first choice of treatment for schizophrenia
b.The SDAs affect both serotonin and glutamate receptors
c.The SDAs produce more extrapyramidal symptoms than the DRAs
d.The SDAs produce more neurological adverse effects than the DRAs
ans:
The SDAs affect both serotonin and glutamate receptors.
a. The serotonin-dopamine antagonists (SDAs) affect both serotonin and glutamate receptors. However, the SDAs produce minimal or no extrapyramidal symptoms and interact with different subtypes of dopamine receptors than do the standard
b. antipsychotics. They also produce fewer neurological adverse effects and are effective in treating negative symptoms of schizophrenia. They are at least as effective as haloperidol for positive symptoms and are uniquely effective for the negative symptoms. These drugs have replaced the dopamine receptor antagonists as the drug of first choice for the treatment of schizophrenia.